{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-010323","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.307616+00:00","generated_at":"2026-06-19T17:55:56.225648+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Citius Pharma reports Q1 net loss of $3.6M ($0.02/sh); cash runway through Feb 2024","bullets":["Net loss of $3.6M ($0.02 EPS) improved from $9.2M ($0.06 EPS) in Q1 2022.","Cash and equivalents $36.9M; runway expected to fund operations through Feb 2024.","I/ONTAK BLA under FDA review with PDUFA target date July 28, 2023.","Mino-Lok Phase 3 trial expanding; enrollment uptick in U.S. and India.","Director Dennis McGrath elected, replacing Dr. William Kane."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-010323","json":"https://secwatch.observer/filing/0001213900-23-010323.json","markdown":"https://secwatch.observer/filing/0001213900-23-010323.md","text":"https://secwatch.observer/filing/0001213900-23-010323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/0001213900-23-010323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/ea173123-8k_citiuspharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T17:55:56.225648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0fefe36ca72a4d83958e5c141d25f17ecfb0d1c","claim":"Citius Pharmaceuticals, Inc. reported the fiscal first quarter ended December 31, 2022 results: net income Net loss was $3.6 million, or ($0.02) per share, EPS $0.02.","evidence_excerpt":"On February 10, 2023, we issued a press release announcing our results of operations for the first quarter of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/0001213900-23-010323-index.htm","confidence":0.87,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal first quarter ended December 31, 2022"},{"label":"Net income","value":"Net loss was $3.6 million, or ($0.02) per share"},{"label":"EPS","value":"$0.02"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}